NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218 It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor.
See also AB-FUBINACA NESS-0327 SR-144,528
References